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Abstract
Background: Albeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells
involvement in the pathology is still in its early phases of investigation. Proteasome degradation is the key step in the
production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and
regulation of autoreactive CD8+ T cells in Multiple Sclerosis.
Methodology/Principal Findings: Immunoproteasomes and PA28-ab regulator are present in MS affected brain area and
accumulated in plaques. They are expressed in cell types supposed to be involved in MS development such as neurons,
endothelial cells, oligodendrocytes, macrophages/macroglia and lymphocytes. Furthermore, in a genetic study on 1262
Italian MS cases and 845 controls we observed that HLA-A*02+ female subjects carrying the immunoproteasome LMP2
codon 60HH variant have a reduced risk to develop MS. Accordingly, immunoproteasomes carrying the LMP2 60H allele
produce in vitro a lower amount of the HLA-A*0201 restricted immunodominant epitope MBP111–119.
Conclusion/Significance: The immunoproteasome LMP2 60HH variant reduces the risk to develop MS amongst Italian HLA-
A*02+ females. We propose that such an effect is mediated by the altered proteasome-dependent production of a specific
MBP epitope presented on the MHC class I. Our observations thereby support the hypothesis of an involvement of
immunoproteasome in the MS pathogenesis.
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Introduction
Multiple Sclerosis (MS) is the most common autoimmune
disorder of the central nervous system (CNS). It is characterized by
multifocal areas of demyelization (plaques), chronic inflammation
and damage to oligodendrocytes and neurons. The cause of MS is
still unknown and disease pathways are poorly understood.
However, the association of HLA-DRB1*15 and other HLA class
I (e.g. HLA-A*02 and HLA-A*03) and class II alleles, the presence
of autoreactive T lymphocytes together with other inflammatory
cells and cytokines in active MS lesions suggest an autoimmune
pathogenesis. Accordingly, the experimental autoimmune enceph-
alomyelitis (EAE), a classical mouse model for MS, can be induced
by the administration of myelin antigens or CD4+ and CD8+ T
lymphocytes specific for those antigens [1,2,3]. On the basis of
recent results on EAE, it has been proposed that the first bout of
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the disease is mediated by CD8+ T cells while the first relapse and
further disease are mediated by CD4+ T cells through different
mechanisms such as antigen release and epitope spreading [4].
The antigen bound on Major Histocompatibility Complex class
I (MHC-I) and presented to the T cell receptor (TCR) of CD8+ T
cells, is normally produced by proteasomes. One of the
proteasome isoforms, known as immunoproteasome, enhances
the generation of specific antigenic epitopes [5] and its role in
neurodegenerative diseases has recently been described [6,7].
Immunoproteasome differs from the constitutive proteasome by
the b subunits with catalytic activity [b1, b2, b5 into constitutive
proteasome and Low Molecular Mass Polypeptide 2 (LMP2),
Multicatalytic Endopeptidase Complex Subunit (MECL-1) and
LMP7 into immunoproteasome] [5]. Immunoproteasome assem-
bly can be induced by IFN-c, which also stimulates the expression
of proteasome activator-ab (PA28-ab). This regulatory complex
binds to the end of the 20S proteasome core, increasing the
cleavage rate in an ATP-independent manner and affecting the
quality of protein digestion [5,8]. Moreover, a role for immuno-
proteasomes has been suggested in some autoimmune diseases
such as ankylosing spondylitis and psoriasis because of the
association of a polymorphism of its LMP2 subunit to the those
pathologies [9,10,11]. This particular polymorphism is a non-
conservative nucleotide base pair change at amino acid position 60
(in exon 3), resulting in two alleles, arginine (R) or histidine (H). It
modifies the susceptibility of peripheral blood mononuclear cells to
TNF-a induced-apoptosis in elderly donors [12], as well as the
proteasome activity in brain protein extracts from Alzheimer
patients and non-demented elderly [7].
In this study, we investigated the presence of immunoprotea-
some in the CNS of MS patients and whether its LMP2
polymorphism might be involved in MS onset. The data we
obtained indicates that immunoproteasomes and PA28-ab
regulator are present in MS CNS and that the LMP2 60HH
genotype impinges upon MS, likely in part by reducing the
production of a specific HLA-A*02 restricted Myelin Basic Protein
epitope (MBP111–119) implicated in MS pathology [13,14,15] as
shown in in vitro assays and in the presence of PA28-ab.
Furthermore, these results add further evidences on the complex
role of HLA-A*02 allele in the pathogenesis of this disease.
Materials and Methods
The Ethics Committees of the University of Bologna, Florence,
Empoli, Milan and Eastern Piedmont approved this study. An
informed written consent to participate in this study was obtained
from all participants.
Patients and Controls
Two independent MS populations were genotyped and
compared to a common Italian control population. The samples
consisted of: i. 694 MS patients (mean age: 38.8+/211.7 years) for
the first MS population consecutively referred to the Department
of Neurology of the University of Florence, the Hospital of Empoli,
the University of Eastern Piedmont (Novara); ii. 568 MS patients
(mean age: 43.4+/212.4 years) for the second MS population
referred to the Institute of Experimental Neurology and
Department of Neurology - San Raffaele Scientific Institute
(Milan) and the IRCCS Fondazione Ospedale Maggiore Policli-
nico (Milan). The two independent samples were compared to a
population of 845 age- and area-matched controls (mean age:
37.8+/212.9 years) and then grouped providing a total MS
sample of 1262 patients (mean age: 41.6+/212.3). Inclusion
criteria were a definite diagnosis of MS [16], age $18 years and
written informed consent. All controls were carefully assessed to
exclude diagnosis of inflammatory disorders. DNA was extracted
from peripheral blood of controls and MS patients as previously
described [12].
Materials and Chemicals
Fetal calf serum and RPMI 1640 medium were from Biowhit-
taker (Belgium). The restriction enzymes were from MBI
Fermentas (Latvia). The peptide MBP102–109 (seq. 102–129 of
the human classical Myelin Basic Protein (MBP) isoform 5) has the
following sequence: PSQGKGRGLSLSRFSWGAEGQRPGF-
GYG-CONH2 term. In bold the sequence of the analyzed epitope
MBP111–119, HLA-A*0201 restricted, detected in MS patient
blood and believed to be involved in MS [13,14,15]. The epitope
(ELA)-MART126–35 used in comparison with MBP111–119 has the
following sequence: ELAGIGILTV-COOH term [17]. All
peptides have been synthesized by Dr. P. Henklein (Institute of
Biochemistry, Medical Faculty Charite´, Berlin, Germany).
Immunohistochemistry (IHC)
In the present study we described ‘‘immunoproteasomes’’ as any
iso-form of proteasome that contains immunosubunits, thereby
also including intermediate-types [18,19]. IHC assays were
performed on parietal lobes and rostral medulla (with MS plaques)
of three MS patients (2 males, 37 and 49 years old; 1 female, 49
years old) and two young controls (females, 21 and 42 years old),
provided by the Department of Hematology and Oncology, ‘‘L.
and A. Seragnoli’’ Section of Anatomic Pathology, University of
Bologna at Bellaria Hospital, Bologna, Italy. The IHC showed in
Figure 1, 2 and 3 referred to autopsy samples derived from MS
and control donors (respectively 49 and 42 years old) died by lung
embolus and gastric hemorrhage, respectively. Both autopsies
were carried out after 24 h from the death and almost all brain was
included for histological examination and diagnostic definition of
the disease. For the present study we selected brain areas carrying
the histopathological features of active chronic plaques. These
plaques, included for our immunohistochemical examination,
were characterized by area of myelin reduction containing
numerous macrophages with clear and foamy cytoplasm, positive
with acid periodic Schiff staining (PAS) after diastase digestion.
The same macrophages contained myelin degradation products,
which reacted with the Luxol Fast Blue (LFB) staining and were
mainly located in the peripheral part of the plaque as previously
described [20]. The presence of macrophages and microglial cells
has been evidenced by anti-CD68 immunostaining. In addition
small venules, surrounded by mature lymphocytes, were present
within the plaques. The lymphocyte population, characterized at
the time of the diagnosis, consisted mainly of mature T cells, CD8
positive. The other MS and controls samples were biopsies
obtained during surgery to investigate the presence of possible
cancers. In the brain of subjects classified as MS patients
characteristic MS lesions, were identified, instead of cancer
markers; in contrast, neither cancer nor MS plaques were
observed in the control sample.
Immunostaining was performed as previously described [7]
adopting a dilution 1:100 of LMP2 and 1:50 of LMP7 antibodies
(Abs) (Affinity- Biomol International, Plymouth Meeting, PA,
USA). In addition, mouse monoclonal Ab to human 20S
proteasome subunit a4 (diluted 1:25; Affinity- Biomol Interna-
tional, Plymouth Meeting, PA, USA) and rabbit polyclonal PA28a
(diluted 1:50; Affinity- Biomol International, Plymouth Meeting,
PA, USA) were used. Double stainings with Abs anti-LMP2 and
anti-CD68 (Dako, Carpintera, CA, USA, diluted 1:150, clone
KP1 that recognizes macrophages/microglial cells), anti LMP2
LMP2 60HH Variant in MS
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and anti-CD45RB (Dako, Carpintera, CA, USA, diluted 1:600;
Abs from clones 2B11 + PD7\26 that recognizes antigens clustered
as CD45RB specific for mature lymphocytes) were performed to
identify microglia/macrophages or to distinguish between oligo-
dendrocytes and lymphocytes. In addition, oligodendrocytes
identification was also carried out by double immunostaining with
anti-LMP2 and anti-Olig2 (Chemicon, Billerica, MA,USA; dilution
1:300; polyclonal rabbit that recognizes the transcription factor
Olig2 [21] specific for oligodendrocytes) as well as anti-PA28-a and
anti-Olig2. Double immunostainings with anti-LMP2 and anti-
CD45RB or anti-CD68 were performed according to the following
procedure: after biotinylated goat anti-polyvalent, two types of
streptavidin were used, the first conjugated with peroxidase (Lab
VISION Ultra vision Large Detection System Anti-polyvalent
HRP, Fremont, CA, USA) and the second with alkaline
phosphatase (DakoCytomation ChemMate Detectin Kit, Alkaline
Phosphatase/RED, Rabbit/Mouse K5005, Carpintera, CA, USA)
and two different chromogens: 3,39-diaminobenzidine (Dako Liquid
DAB-substrate- Chromogen system K3468, Carpintera, CA, USA)
for streptavidin peroxidase and the fast red Working solution
(CHROM) (Dako, Carpintera, CA, USA) for alkaline phosphatase.
Double immunostainings with anti-LMP2/anti-Olig2 and with
anti-PA28-a/anti-Olig2 were performed following the previous
procedure but employing as second chromogen Perma\Blue AP
Chromogen (Diagnostic Biosystems, Pleasonton, CA, USA) for
alkaline phosphatase.
Cell Cultures
Lymphoblastoid cell lines (LcLs) are human B lymphocytes
immortalized with Epstein Barr virus (EBV) which mainly express
immunoproteasomes, as previously reported [22]. T2 cell line is a
human T cell leukemia/B cell line hybrid defective in TAP1/
TAP2 and LMP2/LMP7 subunits and expressing the HLA-
A*0201 allele [23]. LcLs and T2 cell lines were cultured in
RPMI1640 medium supplemented with 10% FCS.
Isolation of DNA from LcLs and Genotyping of Patients,
Controls and LcLs
DNA from LcLs was collected from 15*106 cells using TRIZOL
reagent (Life Technologies, Paisley, UK) as previously reported [22].
DNA from donors for the genetic study was obtained from peripheral
blood and genotyped for LMP2 codon 60 polymorphism,HLA-A*02
and HLA-DRB1*15 alleles. LMP2 genotyping was performed using
standard PCR methods and DNA enzymatic digestions as previously
described [12]. Genotyping for HLA-A*02 and HLA-DRB1*15 was
performed by PCR-SSP analysis; as internal controls, regions of
330 bp of b2 microglobulin and 520 bp of MOG (Myelin
Oligodendrocyte Glycoprotein) promoter were amplified.
20S Proteasome and PA28-ab Purifications
PA28-ab and 20S proteasomes were purified from 9 LcLs
(genotyped for LMP2 codon 60 polymorphism) as previously
Figure 1. LMP2 subunit and PA28-ab are expressed in CNS cortex and white matter of MS but not of young controls. Example of
cortex (A, C) and plaque into white matter (B, D) of MS parietal lobe, stained with anti-LMP2 (A, B) and anti-PA28-a (C, D) Abs are shown. Different cell
types, positive to the staining, are marked as following: 1. neurons; 2. luminal endothelial cells; 3. astrocytes; 4. oligodendrocytes (putative). Example
of a parietal lobe cortex (E, G) and white matter (F, H) of young control stained with anti-LMP2 (E, F) and anti-PA28-a (G, H) Abs, which bind only
luminal endothelial cells (see arrow). In (I) and (L) example of a parietal lobe white matter of a MS patient stained with anti-b1 and anti-a4 Abs are
shown, respectively. As expected, all cells are positive to both stainings. The representative samples here reported derived from gender- and age-
matched MS and control samples. A, C, D, F, G, H, I scale bars = 50 mm; B, E, L scale bars = 25 mm.
doi:10.1371/journal.pone.0009287.g001
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described [8]. The final step of the PA28-ab purification was the
fractioning by chromatography on a phenylsepharose column of
pooled material obtained from all the LCLs. Isolated PA28-ab
stimulated proteasomal activity on Suc-LLVY-MCA substrate up
to five-fold and no activity was observed in controls without 20S
proteasome testifying the absence of protease contamination in the
PA28-ab preparation. Final purified PA28-ab was tested on SDS-
PAGE and stained with Comassie-Blue.
Digestion of Long Substrates, Epitope Detection and
Their Quantification by Mass Spectrometry
The digestion of the synthetic peptide MBP102–129 by purified
20S proteasomes+/2PA28-ab was performed in Hepes buffer in
different condition. In particular, to examine the effects of LMP2
polymorphism on MBP102–129 degradation, 20 mg MBP102–129
peptide was dissolved in 100 ml buffer-1 (20 mM Hepes pH 7.8,
2 mM MgAcetate, 1 mM dithiothreitol) and incubated with
0.5 mg 20S proteasome or dissolved in 100 ml buffer-2 (20 mM
Hepes pH 7.8, 1 mM dithiothreitol) and incubated with 0.25 mg
20S proteasome+3 ml PA28-ab. To examine the effects of PA28-
ab on MBP102–129 degradation, 20 mg MBP102–129 was incubated
with 0.25 mg 20S proteasome+/23 ml PA28-ab. Digestions were
stopped by acidic inactivation and samples frozen. Samples were
analyzed by mass spectrometry as previously described [22].
Briefly, they were quantified by C18 reversed phase HPLC
(HP1100, Agilent) followed by an ESI-MS analyses performed
online with a LCQ ion trap mass spectrometer (Thermo Fisher).
Peptides were identified by their molecular masses calculated from
the m/z peaks of the single or multiple charged ions and were
confirmed by tandem mass spectrometry sequencing analyses. To
test the absence of protease contamination in the PA28-ab
preparation, the substrate MBP102–129 was digested in the usual
Figure 2. LMP2 subunit is accumulated in MS plaques. (A)
Cortex, white matter and plaque of MS parietal lobe stained with anti-
LMP2 Ab; an increase of cells expressing LMP2 in the plaque emerges.
(B) In control parietal lobe, cortex and white matter marked with anti-
LMP2 Ab show a detectable staining only in luminal endothelial cells.
The labeling with anti-b1 Ab of the same MS (C) and control (D) brain
area do not show any difference neither between MS and control nor
between grey and white matters. (E) Rostral medulla, with MS plaque
into inferior olivar nucleus (arrow), stained with anti-LMP2 Ab, which
mainly binds the MS plaque. The representative samples here reported
derived from gender- and age-matched MS and control samples. A-D
scale bars = 300 mm; E scale bar = 3 mm.
doi:10.1371/journal.pone.0009287.g002
Figure 3. LMP2 subunit and PA28-ab are expressed in different
cell types, including oligodendrocytes, macrophages and
microglial cells in MS brains. A) To discriminate among oligoden-
drocytes and lymphocytes, we performed a double staining with anti-
LMP2 (brown) and anti- CD45RB (red) Abs in parietal lobe of MS brains.
Many oligodendrocytes (only brown stained; marked with 1) and
lymphocytes (brown and red stained; marked with 2) are visible. B)
Oligodendrocyte identification was confirmed by staining the same
area with anti-LMP2 (brown) and anti-Olig2 (blue) Abs and observing a
clear labeling of oligodendrocytes for both Olig2 and LMP2 (marked by
arrow). C) Oligodendrocytes (marked by arrow) express also PA28-ab as
emerged by the double staining of MS parietal lobe with anti-PA28-a
(blue) and anti-Olig2 (brown). A double staining for LMP2 (brown) and
CD68 (red) verified that microglia/macrophages (marked with arrows)
express the immunoproteasome subunit in parenchyma (D) and
perivascular (E) parietal lobe of MS brains. F) Microglia/macrophages
(marked with arrows) also express PA28-ab as revealed by the double
staining with anti-PA28-a (blue) and anti-CD68 (brown) Abs. A, E scale
bars = 25 mm; B, C scale bars = 10 mm. D, F scale bars = 50 mm.
doi:10.1371/journal.pone.0009287.g003
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digestion solution without 20S proteasomes for 60 mins and no
detectable degradation of the substrate was observed. Moreover,
when 20S proteasomes were inhibited by MG132 (final concen-
tration of 5 mM) no substrate degradation was observed,
confirming the absence of other proteases in the 20S proteasome
preparation. The impact of LMP2 R60H polymorphism on
MBP102–129 degradation was tested computing the degradation
rate constant (K1) in a reaction of first order. The Specific
Production (SP) of the fragments 10–18 (MBP111–119 epitope) by
20S immunoproteasomes +/2 PA28-ab carrying different LMP2
60 variants was computed as following: (fragment signal)/(signal of
substrate degraded) multiplied for a factor of 1000 (to facilitate the
comparison by readers). The SP provided de facto an estimation of
the epitope produced per digested substrate based on the mass
spectrometry signal. Only peptide signals in samples with similar
substrate degradation and less than 50% of substrate consumption
were compared to minimize errors during peptide quantification
and the re-entry of products in the proteasome core, consequently
obtaining epitope SP by 20S proteasomes carrying different LMP2
codon 60 variants at different percentage of substrate degraded
(,25%, between 25% and 35%, between 35% and 50%).
Flow Cytometric Analysis of the Binding Affinity of
Epitopes-HLA-A*0201
T2 cells (36105 cells/ml) were incubated with various concen-
trations of peptides MBP111–119 or (ELA)-MART126–35 (100–
0,1 mg/ml) in serum-free RPMI 1640 medium for 16h. After-
wards, cells were washed and incubated with anti-HLA-A*02 Ab-
FITC and the HLA-A*02 stabilization on cell surface by bound
epitope was measured by flow cytometer FACScalibur. Net
fluorescence reported in Fig. S1 was computed by subtraction of
fluorescence detected in control samples (with Ab and without
peptides).
Statistical Analyses
Statistical analyses of in vitro digestion data were performed
using the tests of Monte Carlo Anova to evaluate the effect of
LMP2 R60H polymorphism, t-student for independent samples to
evaluate the effect of LMP2 60H allele and Mann-Whitney test to
evaluate the effect of PA28-ab. To compare mass spectrometry
values obtained from different experiments, mass spectrometry
signals were standardized within each degradation set and then
compared. In each data set, homogeneity of variance was checked
by Levene’s test. Comparisons of genetic distributions were
assessed by Monte Carlo Pearson x2 test. Investigation of MS
onset age was performed with Monte Carlo Anova test. Hardy
Weinberg equilibrium was tested using the Pearson x2 test.
p,0.05 was considered statistically significant. All the analyses
were implemented using SPSS software. Pair-wise linkage
disequilibrium was evaluated by two linkage disequilibrium
parameters, Lewontin’s D2 [24] and r2 [25], which were both
calculated in haploview (http://www.broad.mit.edu/mpg/
haploview/) [26].
Results
Immunoproteasome Subunits Are Present in the CNS of
MS Patients (and Concentrated in MS Plaques) but Not of
Young Controls
Although the mechanisms of MS are still largely unknown, some
cell types seem to be involved in the pathogenesis of this disease.
Therefore, we first investigated if immunoproteasome and PA28-
ab subunits are expressed in MS CNS and in which cells. Grey
and white matters of parietal lobe from three MS patients and two
young controls were initially stained with Abs specific for
constitutive proteasome (b1), immunoproteasome (LMP2 &
LMP7) and PA28-a subunits. In the cortex (Fig. 1A) and in the
plaques of the white matter (Fig. 1B) of MS patients, LMP2 was
detected in different cell types. Similar results were obtained
staining the same area with Abs anti-LMP7 (data not shown) and
anti-PA28-a (Fig. 1C, D). In contrast, all stainings were negative
both in cortex and white matter of the same CNS area of young
controls except for luminal endothelial cells, which were positive to
anti-LMP2 (Fig. 1E, F) and anti-PA28-a (Fig. 1G, H) Abs. As
expected, proteasome b1 and a4 subunits were expressed in all cell
types, both in MS patients (Fig. 1I & L, respectively) and in young
controls (data not shown).
Moreover, LMP2 expression was predominant in MS plaques
(Fig. 2A) compared to pre-plaque white matter and cortex while in
the same CNS area of control only luminal endothelial cells were
stained (Fig. 2B). Otherwise, b1 subunit was equally distributed in
grey and white matter of MS (Fig. 2C) and control (Fig. 2D). Such
an accumulation of the immunoproteasome subunit in the plaque
area was even more evident in the rostral medulla of a MS patient
stained with Ab anti-LMP2, which mainly spotted the plaque into
inferior olivar nucleus, whereas other areas were weakly stained
(Fig. 2E).
Immunoproteasome and PA28-ab Subunits Are
Expressed in Different Cell Types in the CNS of MS
Patients
In the CNS areas affected by the disease, LMP2 and PA28-ab
were expressed in different cell types such as neurons, luminal
endothelial cells, astrocytes (Fig. 1A, C) and, in white matter
plaques, also in (putative) oligodendrocytes (Fig. 1B, D). To verify
that oligodendrocytes express LMP2 & PA28-ab and to
distinguish them from lymphocytes, we performed a double IHC
staining of MS parietal lobe slices using Abs anti-LMP2 (or anti-
PA28-a) and anti-CD45RB (marker of mature lymphocytes). As
shown in Figure 3A, lymphocytes present in white matter were
positive to anti-LMP2 and anti-CD45RB staining. In addition,
small rounded nuclei, positive to anti-LMP2 and negative to anti-
CD45RB Abs, corresponding to oligodendrocytes, were present.
This result was further confirmed by anti-LMP2 and anti-Olig2
labeling of the same MS brain area where oligodendrocytes were
positive to both LMP2 and the oligodendrocytes transcription
factor Olig2, while other cells were only stained for LMP2
(Fig. 3B). Similarly, PA28-ab was detected in oligodendrocytes,
positive to both anti-PA28-a and anti-Olig2 Abs (Fig. 3C).
Furthermore, we performed IHC double staining with Abs anti-
CD68 (marker of microglial cells and macrophages) and anti-
LMP2 (or anti-PA28-ab) in MS parietal lobe. Microglial cells and
macrophages expressed both CD68 and LMP2 (Fig. 3D, E) as well
as CD68 and PA28-ab (Fig. 3F), proving that immunoprotea-
somes were present in these cell types also in vivo and thus
extending the in vitro observations of Stohwasser and co-workers
[27].
The Immunodominant Epitope MBP111–119 Is Produced In
Vitro by Immunoproteasomes and PA28-ab Increases the
Efficiency of Its Production
To test the involvement of immunoproteasome and its LMP2
R60H polymorphism in MS we investigated one of the major
immunodominant self-epitopes detected in MS patient blood
[13,14,15], i.e. MBP111–119 (HLA-A*0201-restricted). This epitope
bound the MHC–I (HLA-A*0201) with a relative good affinity
LMP2 60HH Variant in MS
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(Fig. S1) and is present in both the classic and golli MBP. This an
important aspect because, as demonstrated in EAE, these two
MBP families can play different roles in central and peripheral
tolerance towards MBP-reactive CD8+ T cells [28,29].
The 28mer peptide (MBP102–129), which contains the epitope
MBP111–119, was digested in vitro by 20S immunoproteasomes in
presence or absence of PA28-ab, which is strongly implicated in
MHC-I antigen presentation by increasing the production of some
epitopes [30,31].
We observed that this regulatory complex increased the
degradation rate of MBP102–129 (Fig. 4A) as well as the MBP111–119
specific production (SP) (M-W U=0; p=0.002), as also indirectly
confirmed by the concomitant higher SP of the flanking peptide 1–9
( M-W U=0; p=0.002) (Fig. 4B).
LMP2 R60H Polymorphism Influences the Efficiency of
MBP111–119 Production by 20S Immunoproteasomes in
the Presence of PA28-ab
To investigate the impact of the LMP2 R60H polymorphism on
the production of the epitope MBP111–119, we performed in vitro
digestions of the substrate MBP102–129 by 20S immunoprotea-
somes (with or without PA28-ab) purified from 9 LcLs carrying
different LMP2 R60H variants. The epitope SP in the presence of
PA28-ab was associated with the LMP2 R60H polymorphism
(F= 15.49; p = 0.004) and was significantly lower (a decrease of
28.8%) in LMP2 H-carriers (t = 8.08; p,0.001) when less than the
25% of the substrate was consumed (Fig. 4C). Such a result was
confirmed by a decreased epitope SP of 28.5% and 21.72% when
25–35% (t = 2.97; p = 0.021) or 35–50% (t = 4.75; p = 0.002) of
substrate was consumed, respectively. Such an association of the
LMP2 R60H polymorphism with the epitope SP was not detected
in the absence of PA28-ab (F = 0.306; p = 0.747, e.g., with 25–35%
substrate consumed) and, accordingly, it was similar between
LMP2 H-carriers and H-not-carriers when less than 25%
(t =20.47; p= 0.962), 25–35% (t =20.77; p = 0.462) and 35–
50% (t = 0.35; p = 0.744) of the substrate was consumed (Fig. 4D).
Although LMP2 polymorphism influenced the epitope SP, it did
not impinge upon the MBP102–129 degradation rate either in the
absence [22] or in the presence of PA28-ab as described by the
comparison of the degradation rate constants K1 (Fig. 4E)
(F = 0.206; p = 0.820).
Figure 4. 20S immunoproteasomes (+ PA28-ab) carrying LMP2 60H allele have a lower SP of the MBP111–119 epitope. (A) Chart shows
the time-dependent kinetics of MBP102–129 degradation increased in presence of PA28-ab. (B) Specific production (SP) [expressed as: (peptide signal/
consumed substrate signal)*1000] of the MBP111–119 epitope (peptide 10–18 of MBP102–129) and of the two flanking peptides 1–9 and 19–28 in
absence or presence of PA28-ab. The values are the average of the SPs measured at different time points. (C) In presence of PA28-ab, H-carrier 20S
immunoproteasomes have a significant lower epitope SP in all three selected ranges of substrate consumption. No significant difference emerged, on
the contrary, in absence of PA28-ab (D). (E) The similar rate constant K1 of MBP102–129 digestion by 20S immunoproteasomes (in presence of PA28-ab)
carrying the three LMP2 codon 60 variants. All values are given as mean+S.E.M. Statistical significance (p,0.05) is marked with *.
doi:10.1371/journal.pone.0009287.g004
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LMP2 60HH Variant Decreases the Risk to Develop MS in
HLA-A*02+ Female Population
As in vitro experiments showed that LMP2 60H allele decreases
the production of the HLA-A*02-restricted MBP111-119 epitope we
performed a genetic population study to test its possible impact on
MS onset. We genotyped two independent samples of 694 and 598
MS patients as well as 845 geographically- and age-matched
controls for LMP2 R60H, HLA-A*02 and HLA-DRB1*15 alleles,
considering their gender. The impact of an alteration of MBP111-
119 production on MS pathogenesis should be evident in patients
able to present such an epitope on HLA-A*02 MHC-I variant.
Accordingly, we compared the LMP2 R60H distribution in HLA-
A*02 positive MS patients and control subjects. Both MS
population showed the same genetic behavior (Table S1 & S2),
hence we grouped them in a MS Italian population of 1262
patients and compared them to the control sample (Table 1). A
significant decrease in LMP2 60HH frequency emerged in female
MS patients carrying the HLA-A*02 allele (e.g. LMP2 60HH vs
RR: p = 0.005; OR = 0.443; 95% CI = 0.249 – 0.790) (Table 2)
but not in HLA-A*02-positive male MS patients (Table 3) nor in
HLA-A*02-negative female and male MS patients (data not
shown). In female controls LMP2 60H was not in linkage
disequilibrium (LD) neither with HLA-DRB1*15 (D’ = 0.02; r2
, 0.001; p. 0.05) nor with HLA-A*02 (D’ = 0.03; r2 = 0.001; p
. 0.05). Both MS and control populations were in Hardy-
Weinberg equilibrium for LMP2 codon 60 polymorphism (data
not shown). Furthermore, HLA-A*02 allele was a protective factor
against MS (p = 0.001; OR = 0.671; 95% CI = 0.529 - 0.851)
while HLA-DRB1*15 allele was a risk factor (p , 0.001; OR =
2.525; 95% CI = 1.801 - 3.754) (data not shown), as already
reported in the Italian population too [3,32,33,34,35]. No effects
on the MS onset age exerted by LMP2 polymorphism in HLA-
A*02-positive female MS population (Table 4) and by HLA-A*02
in the total MS population was observed (Table 5).
Discussion
The observed gender-dependency of the genetic association is
consistent with other studies describing a gender dimorphism in
cytokine response towards myelin antigens and a hormonal
regulation of the immune system in MS [36,37,38]. LMP2 R60H
polymorphism association is gender- (male-) dependent in another
autoimmune disease, i.e. dermal psoriasis [9]. The bulk of these
indirect observations suggest a connection between LMP2 codon 60
polymorphism, immunoproteasome activity and gender in immu-
nological dysfunctions. Despite the scarcity of experimental
evidences we might speculate that the cytokines responses towards
MHC-I myelin epitopes (as demonstrated for the MHC-II [38]) is
altered by gender, generating a scenario in which the influence of
the LMP2 R60H polymorphism on specific myelin epitopes might
Table 1. Gender distribution in Italian MS and control
populations. Values in brackets in distribution column are
percentages. The Italian MS population described in this table
is the result of sum of two independent Italian MS samples
reciprocally in accordance (see also Tables S1 & S2).
MS (n = 1262) control (n = 845)
male 413 (32.7) 437 (51.7)
female 849 (67.3) 408 (48.3)
doi:10.1371/journal.pone.0009287.t001
Table 2. LMP2 60HH variant decreases the risk to develop MS
in HLA-A*02 carrier female population. Values in brackets in
distribution column are percentages. Statistical results are
reported for each genetic analysis. The Italian MS female
population described in this table is the result of sum of two
independent Italian MS samples reciprocally in accordance
(see also Tables S1 & S2).
Genotype MS (n = 337) control (n = 202) p OR (95% CI)
HH 26 (7.7) 32 (15.8)
RH 146 (43.3) 80 (39.6) 0.013
RR 165 (49.0) 90 (44.6)
HH vs RR 0.005 0.443 (0.249–0.790)
HH vs RH 0.006 0.445 (0.248–0.799)
RH vs RR 0.981 0.995 (0.684–1.448)
Allele MS (n = 674) control (n = 404) p OR (95% CI)
H 198 (29.4) 144 (35.6) 0.032 0.840 (0.713–0.989)
R 476 (70.6) 260 (64.4)
doi:10.1371/journal.pone.0009287.t002
Table 3. LMP2 R60H distribution in HLA-A*02 carrier MS and
control male populations. Values in brackets in distribution
column are percentages. Statistical results are reported for
each genetic analysis. The Italian MS male population
described in this table is the result of sum of two independent
Italian MS samples reciprocally in accordance (see also Tables
S1 & S2).
Genotype MS (n = 178) control (n = 194) p OR (95% CI)
HH 18 (10.1) 21 (10.8)
RH 85 (47.8) 88 (45.4) 0.281
RR 75 (42.1) 85 (43.8)
HH vs RR 0.728 0.868 (0.389–1.933)
HH vs RH 0.948 1.026 (0.468–2.248)
RH vs RR 0.501 0.846 (0.518–1.379)
Allele MS (n = 356) control (n = 388) p OR (95% CI)
H 121 (34.0) 130 (33.5) 0.579 0.908 (0.646–1.276)
R 235 (66.0) 258 (66.5)
doi:10.1371/journal.pone.0009287.t003
Table 4. LMP2 R60H polymorphism and MS onset age in
HLA-A*02 carrier female MS population. Means and standard
deviations (SD) are reported. The Italian HLA-A*02 carrier
female MS population described in this table is the result of
sum of two independent Italian MS samples reciprocally in
accordance (see also Tables S1 & S2).
Genotype mean (years) SD p
HH 32.61 7.65 0.329
RH 29.48 9.65
RR 30.65 10.57
doi:10.1371/journal.pone.0009287.t004
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impinges upon the MS onset only in females. Indeed, the decreased
risk of female subjects carrying the HLA-A*02 allele and the LMP2
60HH variant to develop MS might be explained by the impact of
the LMP2 polymorphism on the generation of the HLA-A*02-
restricted epitope (MBP111–119) as well of other epitopes not
investigated in this study. Indeed, the decreased presentation of
this epitope on the MHC-I (HLA-A*02) complex of antigen
presenting cells or other cells involved inMS pathways could reduce
the probability to disrupt the physiological tolerance (central or
peripheral) of MBP-reactive CD8+ T cells and/or their cytotoxicity
towards oligodendrocytes thereby restraining the MS onset. We
showed that the main producers of myelin sheets, i.e. the
oligodendrocytes, as well as the macrophages/microglial cells,
which express PA28-ab [39] and golli MBP [40] during EAE, are
positive to LMP2 and PA28-ab staining in MS CNS (Fig. 3). In
oligodendrocytes, a decreased presentation mediated by the LMP2
60HH variant of MBP epitopes (e.g. MBP111–119) on HLA-A*02
MHC could attenuate the cytotoxic activity of MBP-reactive CD8+
T cells against their main cell targets. In macrophages/microglial
cells (Fig. 3), the lower presentation of these epitopes could restrain a
further clonal expansion of self-reactive CD8+ T cells, which has
been assumed as one of the key steps of MS development [1].
Taking into account that CNS endothelial cells express immuno-
proteasomes and PA28-ab (Fig. 1) as well as they can present MBP
in animal models [41,42,43], the LMP2 60HH-dependent altered
expression of the MBP epitopes (e.g. MBP111–119) might also affect
the blood-brain barrier (BBB) crossing. Indeed, it has been recently
proposed that, after priming, activated CD8+ T cells cross the BBB
by an antigen-specific interaction with cerebral endothelium [44].
Thus, endothelial cells carrying HLA-A*02 and LMP2 60HH
might lead to a decreased BBB crossing by MBP-reactive CD8+ T
cells during the early phases of neuroinflammation, affecting MS
development. Furthermore, LMP2 R60H polymorphism might
influence not only the mechanisms leading toMS that occur in CNS
but also the complex balance between central and peripheral
tolerance of MBP-restricted CD8+ T cells and thereby their
pathological activation in peripheral lymph nodes (e.g. cervical and
lumbal) by dendritic cells [1]. Indeed, these cells, which express
immunoproteasomes and PA28-ab at their mature stage [45], play
a key role in the thymic selection and in peripheral activation of
MBP-restricted CD8+ T cells by the presentation of endogenous
MBP on MHC-I [28,29]. As consequence, an alteration of the
amount of MBP epitopes (e.g. MBP111–119) presented on dendritic
cells due to the LMP2 polymorphism might affect the repertoire of
MBP-reactive CD8+ T cells and, thereby their eventual activation
during the early phases of MS onset.
Our investigation also addresses the complex role that HLA-
A*02 appears to have in MS. We observed a decreased risk to
develop MS in Italian female population carrying the HLA-A*02
allele, in agreement with other studies [32,33,46]. Although the
mechanisms are still unknown, HLA-A*02 variant in a specific
EAE model appeared to increase the negative selection of MBP-
reactive CD8+ thymocytes and to decrease the responsiveness of
MBP-reactive CD8+ T cells in periphery [4], thereby protecting
from EAE. Our results suggest that LMP2 60HH variant impinges
upon the likelihood to develop MS but only in HLA-A*02 carriers.
Likewise, LMP2 60H allele decreases the in vitro generation of the
MBP111–119 epitope by immunoproteasomes thereby suggesting
that this specific myelin epitope could play a pathogenetic role in
MS when presented on HLA-A*02 MHC. Accordingly, several
CD8+ T cells reactive to HLA-A*02 myelin epitopes have been
identified in peripheral blood of MS subjects [14]. In particular,
MBP111–119–reactive CD8+ T cells, which are increased three fold
in MS patients peripheral blood, are CD45RO+ memory T cells
secreting TNF-a and IFN-c after epitope challenging and are
cytotoxic towards antigen presenting cells and oligodendrocytes,
thus supporting the postulate that these CD8+ T cells could
contribute to the tissue injury in MS [13,15].
In conclusion, our data suggests that the presence of
immunoproteasomes in the CNS could be a marker of a
pathological scenario involving neuroinflammation (autoimmuni-
ty, neurodegeneration but also ageing) [6,7,47], therefore putting
immunoproteasome forward as potential candidate for future
therapeutic approaches [48,49,50,51,52].
Supporting Information
Figure S1 MBP111–119 binds the HLA-A*0201 complex with
relative good affinity. A) Comparison of the amount of HLA-
A*0201 complexes (marked with a FITC-Ab) presented on the
outer surface of T2 cells treated with 100 mg/ml MBP111–119 or
(ELA)-MART126–35 epitopes. In particular, signals of T2 cells are
reported: i. without FITC-Ab and epitope; ii. without epitopes and
with FITC-Ab; iii. with FITC-Ab and MBP111–119 epitope; iv.
with FITC-Ab and (ELA)-MART126–35 epitope. B) The chart
shows the binding affinity of the peptides for the MHC class I
complexes presented to the outer surface of T2 cells. The net
fluorescence is the fluorescence’s difference between the cells
incubated with and without the epitopes.
Found at: doi:10.1371/journal.pone.0009287.s001 (2.00 MB TIF)
Table S1 LMP2 60HH, HLA-A*02 and gender frequency in the
first investigated Italian MS population (n = 694) compared to age-
matched Italian control population (n = 845). (A) Gender distri-
bution in MS patients and control populations. (B) LMP2 R60H
polymorphism and allele distribution in MS and control HLA-
A*02 carrier populations, taking into account the gender. (C)
LMP2 R60H polymorphism and MS onset age in HLA-A*02-
positive female MS patients. Values in brackets in distribution
column are percentages. Statistical results are reported for each
genetic analysis.
Found at: doi:10.1371/journal.pone.0009287.s002 (0.14 MB
DOC)
Table S2 LMP2 60HH, HLA-A*02 and gender frequency in the
second investigated Italian MS population (n=598) compared to
age-matched Italian control population (n=845). (A) Gender
distribution in MS patients and control populations. (B) LMP2
R60H polymorphism and allele distribution inMS and control HLA-
A*02 carrier populations, taking into account the gender. (C) LMP2
R60H polymorphism and MS onset age in HLA-A*02-positive
female MS patients. Values in brackets in distribution column are
percentages. Statistical results are reported for each genetic analysis.
Found at: doi:10.1371/journal.pone.0009287.s003 (0.14 MB
DOC)
Table 5. MS onset age in HLA-A*02 carrier and not-carrier MS
populations. Means and standard deviations (SD) are
reported. The Italian MS population described in this table is
the result of sum of two independent Italian MS samples
reciprocally in accordance (see also Tables S1 & S2).
HLA-A* mean (years) SD p
02 not-carriers 31.11 10.79 0.206
02 carriers 30.27 10.21
doi:10.1371/journal.pone.0009287.t005
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